These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. Luke CJ; Carner K; Liang X; Barbour AG J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201 [TBL] [Abstract][Full Text] [Related]
5. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. Comstedt P; Schüler W; Meinke A; Lundberg U PLoS One; 2017; 12(9):e0184357. PubMed ID: 28863166 [TBL] [Abstract][Full Text] [Related]
6. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis. Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431 [TBL] [Abstract][Full Text] [Related]
7. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Luke CJ; Huebner RC; Kasmiersky V; Barbour AG Vaccine; 1997; 15(6-7):739-46. PubMed ID: 9178476 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model. Schwendinger MG; O'Rourke M; Traweger A; Savidis-Dacho H; Pilz A; Portsmouth D; Livey I; Barrett PN; Crowe BA PLoS One; 2013; 8(11):e79022. PubMed ID: 24260146 [TBL] [Abstract][Full Text] [Related]
9. Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter. Simon MM; Gern L; Hauser P; Zhong W; Nielsen PJ; Kramer MD; Brenner C; Wallich R Eur J Immunol; 1996 Dec; 26(12):2831-40. PubMed ID: 8977275 [TBL] [Abstract][Full Text] [Related]
10. Design and development of a novel vaccine for protection against Lyme borreliosis. Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015 [TBL] [Abstract][Full Text] [Related]
11. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Probert WS; LeFebvre RB Infect Immun; 1994 May; 62(5):1920-6. PubMed ID: 8168958 [TBL] [Abstract][Full Text] [Related]
12. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378 [TBL] [Abstract][Full Text] [Related]
13. Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype. Schaible UE; Wallich R; Kramer MD; Gern L; Anderson JF; Museteanu C; Simon MM Vaccine; 1993; 11(10):1049-54. PubMed ID: 8212826 [TBL] [Abstract][Full Text] [Related]
14. Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice. Bockenstedt LK; Fikrig E; Barthold SW; Flavell RA; Kantor FS J Immunol; 1996 Dec; 157(12):5496-502. PubMed ID: 8955199 [TBL] [Abstract][Full Text] [Related]
15. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis. Fawcett PT; Rose CD; Budd SM; Gibney KM Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199 [TBL] [Abstract][Full Text] [Related]
16. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease. Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567 [TBL] [Abstract][Full Text] [Related]
17. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Scheckelhoff MR; Telford SR; Hu LT Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863 [TBL] [Abstract][Full Text] [Related]
18. Pre-exposure Prophylaxis With OspA-Specific Human Monoclonal Antibodies Protects Mice Against Tick Transmission of Lyme Disease Spirochetes. Wang Y; Kern A; Boatright NK; Schiller ZA; Sadowski A; Ejemel M; Souders CA; Reimann KA; Hu L; Thomas WD; Klempner MS J Infect Dis; 2016 Jul; 214(2):205-11. PubMed ID: 27338767 [TBL] [Abstract][Full Text] [Related]
19. Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice. Meirelles Richer L; Aroso M; Contente-Cuomo T; Ivanova L; Gomes-Solecki M Clin Vaccine Immunol; 2011 Nov; 18(11):1809-16. PubMed ID: 21918116 [TBL] [Abstract][Full Text] [Related]
20. The Lyme disease vaccine takes its toll. Thomas V; Fikrig E Vector Borne Zoonotic Dis; 2002; 2(4):217-22. PubMed ID: 12804162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]